Clinical Trials
519
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (363 trials with phase data)• Click on a phase to view related trials
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: HRS-4642+AG +Adebrelimab
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT07131514
Sedation and Analgesia Bundled Strategies Among ICU Nurses
- Conditions
- Sedation and AnalgesiaDeliriumFamily Invlovement/EmpowermentEarly Mobilization
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 228
- Registration Number
- NCT07132450
Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Biological: SC01009 injectionBiological: Placebo Group(Vehicle)
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT07131150
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳China-Japan Friendship Hospital, Beijing, Beijing, China
Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Relapsed and Refractory DLBCL
- Interventions
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT07122609
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%
- Conditions
- Prostate CancerProstate Adenoma
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 270
- Registration Number
- NCT07115992
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 104
- Next
News
Zambon Secures Chinese Approval for Intravenous Fluimucil Following Successful Phase 3 Trial
Zambon has received Chinese regulatory approval and launched the intravenous formulation of Fluimucil (N-acetylcysteine) for treating respiratory diseases with excessive mucus secretion.
CirCode Biomed's HM2002 Becomes World's First Circular RNA Drug to Receive FDA IND Clearance for Ischemic Heart Disease
CirCode Biomed announced FDA clearance for HM2002, marking the first circular RNA drug to receive IND approval for ischemic heart disease treatment.